Biotech is attracting more and more investors

A woman looks through a microscope.

(25.05.2022) The Swiss biotech industry succeeded in raising CHF 3.33 billion in 2021. According to the Swiss Biotech Report 2022, the research and development sector alone attracted a record CHF 2.56 billion in investments.

Swiss biotech companies are experiencing their second highest level of investment on record. Large biotech companies are coveting access to the U.S. NASDAQ stock market, while small and medium-sized companies can now rely on the new Sparks Market of SIX Swiss Exchange to go public. "The levels of funding seen in 2021 have been exceptional," says Michael Altorfer, CEO of the Swiss Biotech Association. 

Of the total 3.33 billion invested, 2.51 billion was in listed companies. Basel-based companies Idorsia and Bachem managed to raise 600 million and 584 million respectively. Sophia Genetics (234 million), CRISPR Therapeutics (229 million) and Polypeptide (191 million) came next. In addition, 817 million was injected into the sector via private funds, the main beneficiaries of which were Anaveon (110 million) and Numab Therapeutics (100 million). 

In 2021, the Swiss biotech industry generated a turnover of 6.7 billion, up 36.7% compared to 2020. The number of employees in the research and development sector, which mobilized a record 2.56 billion, increased by 9.5% in 2021.


Information

Last modification 25.05.2022

Top of page

News and useful information for founders and entrepreneurs.
https://www.kmu.admin.ch/content/kmu/en/home/New/news/2022/biotech-is-attracting-more-and-more-investors.html